Enveric Unveils Positive Results From Animal Studies Of Its Psilocin Prodrug For Anxiety
Portfolio Pulse from Vuk Zdinjak
Enveric Biosciences (NASDAQ:ENVB) has announced positive results from pharmacokinetic animal studies of its lead product candidate, EB-373, a psilocin-prodrug targeting anxiety disorders. The studies demonstrated oral bioavailability, rapid onset of action, systemic clearance, and a favorable side effect profile. The company plans to present thorough analyses of the studies at a future scientific conference.
July 17, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive results from animal studies of Enveric Biosciences' lead product candidate, EB-373, could boost investor confidence and potentially lead to a short-term increase in the company's stock price.
Positive results from clinical trials often lead to increased investor confidence, which can result in a short-term increase in a company's stock price. Given that EB-373 is Enveric Biosciences' lead product candidate, these results are particularly significant and relevant to the company's overall performance.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100